MiNK Therapeutics rises as it wins funding for child cancer cell therapy

Mink Therapeutics

10/03/2026 09:57

** Shares of drug developer MiNK Therapeutics INKT.O rise 53.40% to $5.58 premarket

** Co says it will receive up to $1.1 mln from C-Further to develop a cell therapy for childhood cancers

** Therapy targets PRAME, a protein linked to hard‑to‑treat cancers including sarcomas, acute myeloid leukemia and medulloblastoma, co says

** Co says donor‑derived immune cells are designed to allow faster treatment without complex matching

** Researchers at University of Southampton to run preclinical safety and efficacy studies, co says

** Co's lead candidate, agenT‑797, is already being tested for other conditions - INKT

** Share up ~60% in 2025

 (Reporting by Sahil Pandey in Bengaluru)

 ((Sahil.Pandey@thomsonreuters.com))